European Society for Medical Oncology (ESMO 2022) - Abstract publication schedule

Online Programme available here

Publication schedule of accepted abstracts:

Abstracts	Date and time
Regular abstracts accepted as: Proffered Paper (suffix ‘O’) Mini Oral (suffix ‘MO’) Poster (suffix ‘P’) Poster (suffix ‘TiP’) EONS Poster (prefix ‘CN’)	Monday, 5 September 2022 00:05 Central European Summer Time (CEST)
All late-breaking abstracts (prefix ‘LBA’)	Thursday, 8 September 2022 00:05 Central European Summer Time (CEST)
Dedicated embargo for LBA1 and 903O	Friday, 9 September 2022 00:05 Central European Summer Time (CEST)
Dedicated embargo for LBA10	Monday, 12 September 2022 00:05 Central European Summer Time (CEST)

1. All regular abstracts accepted for presentation at ESMO 2022 as Proffered Paper (suffix O), Mini Oral (suffix MO), Poster (suffix P or TiP) will be published online via the ESMO website at 00:05 CEST on Monday, 5 September 2022.
2. All Late-breaking abstracts accepted for presentation at ESMO 2022 as Proffered Paper or Mini Oral (prefix LBA) will be published online via the ESMO website at 00:05 CEST on Thursday, 8 September 2022.
3. LBA1 and Abstract 903O will be published online via the ESMO website at 00:05 CEST on Friday, 9 September 2022.
4. LBA10 will be published online via the ESMO website at 00:05 CEST on Monday, 12 September 2022.
5. The official hashtag is #ESMO22: using it will allow you to join the conversation around the Congress
6. To follow ESMO on Social Media:

Twitter 

Facebook 

LinkedIn 

Instagram 

YouTube

Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, to further leverage the GuardantINFORM real-world evidence (RWE) platform to help accelerate development efforts for Merck KGaA, Darmstadt, Germany‘s precision oncology pipeline. The expanded strategic collaboration will focus on therapy development for core cancer indications with significant unmet need.

Under the expanded collaboration, Merck KGaA, Darmstadt, Germany, will work closely with data scientists at Guardant Health on a variety of therapy development initiatives that utilize the genomics and clinical information accessible through the GuardantINFORM platform.

About GuardantINFORM

The GuardantINFORM clinical-genomic platform is intended to help accelerate research and development of the next generation of cancer therapeutics by offering biopharma partners an in-silico platform that combines de-identified longitudinal clinical information and genomic data collected from the Guardant360 liquid biopsy test. With data from more than 225,000 patients diagnosed with locally advanced and metastatic cancers, this robust dataset offers real-world insights into anti-cancer therapy use in the clinic, tumor evolution, and treatment resistance throughout each patient’s treatment journey for many advanced solid tumor cancers, including non-small cell lung, breast, colon, and prostate.